Innovative Heart Health Technology on Your Wrist

Cardiac Markers is launching breakthrough technology that can turn millions of connected, wearable devices into precision health medical devices. Based in the heart of the world’s leading health technology innovation cluster, Minnesota’s Medical Alley, Cardiac Markers has developed proprietary software which enhances the abilities to capture diagnostic data from a single lead ECG device, going far beyond the simple smart watch. Cardiac Markers has also licensed a proprietary research algorithm designed to quantify and predict the risk of death from a cardiac event. This algorithm will expand our risk management reporting.

Cardiac Markers’ technology is designed to collect single-lead electrocardiogram (ECG) data from the world’s most used fitness and smartwatch devices to identify P waves and screen for atrial fibrillation (AFib), calculate heart rate variability (HRV), QTc, QT Variability Index (QTVI) and measure the heart’s ability to contract effectively. Data is downloaded from the smartwatch to the user’s smartphone or tablet and forwarded to the Cardiac Markers’ ECG cloud-based analysis server. Data analyses are automatically processed and a real-time report is sent to the user’s email or directly to their telehealth doctor.

The Cardiac Markers’ analysis report indicates a normal or abnormal finding for all metrics measured. This information assists physicians in analyzing a patient’s cardiac condition.

Cardiac Markers is poised to assist the burgeoning telehealth market with software that will reduce the need to visit a doctor’s office or hospital. There is a significant opportunity for growth and profitability.

Telehealth please take notice of the significant opportunity for growth as you create add on profitability through the use of the Cardiac Markers targeted ECG software.

There are more than 260 drugs that cause QT lengthening which increases the potential for serious heart problems. Widespread QT self-monitoring for drug toxicity is an immediate need. The measurements to prevent death due to a prolonged QT will be easily managed by associating a consumer’s compatible fitness or smartwatch device with the Cardiac Markers’ service.

Cardiac Markers’ software is currently in phase II testing with strong results. The opportunity to make a life difference for millions of patients exists. There are multiple health technology markets for this product including the smartwatch, fitness device and home health sectors. Wearable device manufacturers and clinicians focused on heart health are likely to add the Cardiac Markers’ ECG screening service as an emerging, breakthrough benefit to their offerings